Category

Sci-B-Vac®

VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine

By | Press Releases, Sci-B-Vac®
Vaccination complete in 1,537 subjects in PROTECT Phase 3 study No vaccine-related adverse events have been observed to-date Top-line data expected mid-2019 VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced...
Read More

VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards

By | Cytomegalovirus ("CMV"), Glioblastoma ("GBM"), Press Releases, Sci-B-Vac®
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation of three Scientific and Clinical Advisory Boards (SABs) consisting of leading experts in infectious disease and immuno-oncology research and vaccine...
Read More

VBI Vaccines Reports Positive Outcome from Phase III Pre-IND Discussions with the FDA for Hepatitis B Vaccine, Sci-B-Vac®

By | Press Releases, Sci-B-Vac®
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced today that it has completed a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to...
Read More